Mini-Reviews in Medicinal Chemistry ( IF 3.8 ) Pub Date : 2021-05-31 , DOI: 10.2174/1389557521666210104165733 Maheswara Rao Gokada 1 , Visweswara Rao Pasupuleti 2 , Hari Babu Bollikolla 1
The novel Coronavirus disease (COVID-19) is an epidemic disease that appeared at the end of the year 2019 with a sudden increase in number and came to be considered as a pandemic disease caused by a viral infection which has threatened most countries for an emergency search for new anti-SARS-COV drugs /vaccines. At present, the number of clinical trials is ongoing worldwide on different drugs i.e. Hydroxychloroquine, Remedisvir, Favipiravir that utilize various mechanisms of action. A few countries are currently processing clinical trials, which may result in a positive outcome. Favipiravir (FPV) represents one of the feasible treatment options for COVID-19, if the result of the trials turns out positive. Favipiravir will be one of the developed possibly authoritative drugs to warrant benefits to mankind with large-scale production to meet the demands of the current pandemic Covid-19 outbreak and future epidemic outbreaks. In this review, the authors tried to explore key molecules, which will be supportive for devising COVID-19 research.
中文翻译:
新兴目标和合成抗病毒化合物的方法的简短回顾:COVID-19的角度
新型冠状病毒病(COVID-19)是一种流行性疾病,于2019年底出现,数量突然增加,被认为是由病毒感染引起的大流行性疾病,已威胁到大多数国家的紧急情况寻找新的抗SARS-COV药物/疫苗。目前,全世界正在对利用各种作用机制的不同药物(例如羟氯喹,雷美地韦,法维吡韦)进行大量的临床试验。目前有几个国家正在处理临床试验,这可能会产生积极的结果。如果试验结果显示阳性,则法维拉韦(FPV)代表COVID-19的可行治疗方案之一。Favipiravir将是已开发的可能具有权威性的药物之一,可以保证大规模生产对人类有益,以满足当前的大流行Covid-19疫情和未来的流行病暴发的需求。在这篇综述中,作者试图探索关键分子,这将有助于开展COVID-19研究。